CD36 and breast carcinoma: In breast cancer, some studies have indicated that high CD36 expression enhances the proliferation and migration of ER‐positive breast cancer cells while weakening the inhibitory effect of tamoxifen on ER‐positive cell growth [17], suggesting that CD36 plays a role in mediating resistance to ER‐targeted therapies [18].